In this episode of Global Trial Accelerators, we sit down with Justin Chickles, CEO and co-founder of Glycyx Therapeutics, a clinical-stage biotech company taking on a hidden threat to cancer immunotherapy success: opioids.
With over two decades of leadership across therapeutics, diagnostics, and digital health — including roles at Johnson & Johnson and multiple venture-backed startups — Justin shares how Glycyx has advanced axelopran, a first-in-class therapy designed to reverse opioid-induced immunodeficiency, from scientific insight to a Phase 2 clinical trial launching this fall.
